104.33 USD
▼-3.99-3.68%
盘后 104.00 -0.32%
2026-09-15
市值
$680.95M
市盈率
—
EPS
-2.18
股息率
—
52 周区间
46.89 – 124.82
成交量
96.98K
Beta
1.50
目标价
126.31
52W 低 46.8952W 高 124.82
价格走势
公司简介
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging ...